Top

Published in:

01-02-2019 | Original Investigation

Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice

Authors: Aravind Shekar, Shylaja Ramlal, Joseph Kingston Jeyabalaji, Murali Harishchandra Sripathy

Published in: Medical Microbiology and Immunology | Issue 1/2019

Abstract

Escherichia coli O157:H7 with its traits such as intestinal colonization and fecal-oral route of transmission demands mucosal vaccine development. E. coli secreted protein B (EspB) is one of the key type III secretory system (TTSS) targets for mucosal candidate vaccine due to its indispensable role in the pathogenesis of E. coli O157:H7. However, mucosally administered recombinant proteins have low immunogenicity which could be overcome by the use of mucosal adjuvants. The quest for safe, potent mucosal adjuvant has recognized ΔG fragment of Zonula occludens toxin of Vibrio cholerae with such properties. ΔG enhances mucosal permeability via the paracellular route by altering epithelial tight junction structure in a reversible, ephemeral and non-toxic manner. Therefore, we tested whether recombinant ΔG intranasally co-administered with truncated EspB (EspB + ΔG) could serve as an effective mucosal adjuvant. Results showed that EspB + ΔG group induced higher systemic IgG and mucosal IgA than EspB alone. Moreover, EspB alone developed Th2 type response with IgG1/IgG2a ratio (1.64) and IL-4, IL-10 cytokines whereas that of EspB + ΔG group generated mixed Th1/Th2 type immune response evident from IgG1/IgG2a ratio (1.17) as well as IL-4, IL-10 and IFN-γ cytokine levels compared to control. Sera of EspB + ΔG group inhibited TTSS mediated haemolysis of murine RBCs more effectively compared to EspB, control group and sera of both EspB + ΔG, EspB group resulted in similar levels of efficacious reduction in E. coli O157:H7 adherence to Caco-2 cells compared to control. Moreover, vaccination with EspB + ΔG resulted in significant reduction in E. coli O157:H7 fecal shedding compared to EspB and control group in experimentally challenged streptomycin-treated mice. These results demonstrate mucosal adjuvanticity of ΔG co-administered with EspB in enhancing overall immunogenicity to reduce E. coli O157:H7 shedding.

Karmali MA, Gannon V, Sargeant JM (2010) Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 140:360–370CrossRefPubMed

Varela NP, Dick P, Wilson J (2013) Assessing the existing information on the efficacy of bovine vaccination against Escherichia coli o157: H7—a systematic review and meta-analysis. Zoonoses Public Health 60:253–268CrossRefPubMed

Matthews L, Reeve R, Gally DL et al (2013) Predicting the public health benefit of vaccinating cattle against Escherichia coli O157. Proc Natl Acad Sci USA 110:16265–16270. https://doi.org/10.1073/pnas.1304978110 CrossRefPubMedPubMedCentral

Potter AA, Klashinsky S, Li Y et al (2004) Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 22:362–369. https://doi.org/10.1016/j.vaccine.2003.08.007 CrossRefPubMed

McNeilly TN, Mitchell MC, Rosser T et al (2010) Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine 28:1422–1428. https://doi.org/10.1016/j.vaccine.2009.10.076 CrossRefPubMed

Lin R, Zhu B, Zhang Y et al (2017) Intranasal immunization with novel EspA-Tir-M fusion protein induces protective immunity against enterohemorrhagic Escherichia coli O157:H7 challenge in mice. Microb Pathog 105:19–24. https://doi.org/10.1016/j.micpath.2017.01.062 CrossRefPubMed

Wan C, Zhou Y, Yu Y et al (2011) B-cell epitope KT-12 of enterohemorrhagic Escherichia coli O157:H7: a novel peptide vaccine candidate. Microbiol Immunol 55:247–253. https://doi.org/10.1111/j.1348-0421.2011.00316.x CrossRefPubMed

Nart P, Holden N, McAteer SP et al (2008) Mucosal antibody responses of colonized cattle to Escherichia coli O157-secreted proteins, flagellin, outer membrane proteins and lipopolysaccharide. FEMS Immunol Med Microbiol 52:59–68. https://doi.org/10.1111/j.1574-695X.2007.00341.x CrossRefPubMed

Fasano A, Baudry B, Pumplin DW et al (1991) Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 88:5242–5246. https://doi.org/10.1073/pnas.88.12.5242 CrossRefPubMedPubMedCentral

10.

Fasano A, Uzzau S (1997) Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 99:1158–1164. https://doi.org/10.1172/JCI119271 CrossRefPubMedPubMedCentral

11.

Fasano A, Fiorentini C, Donelli G et al (1995) Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 96:710–720. https://doi.org/10.1172/JCI118114 CrossRefPubMedPubMedCentral

12.

Marinaro M, Fasano A, De Magistris MT (2003) Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect Immun 71:1897–1902. https://doi.org/10.1128/IAI.71.4.1897-1902.2003 CrossRefPubMedPubMedCentral

13.

Di Pierro M, Lu R, Uzzau S et al (2001) Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem 276:19160–19165. https://doi.org/10.1074/jbc.M009674200 CrossRefPubMed

14.

Salama NN, Fasano A, Thakar M, Eddington ND (2005) The impact of ∆G on the oral bioavailability of low bioavailable therapeutic agents. J Pharmacol Exp Ther 312:199–205. https://doi.org/10.1124/jpet.104.073205 CrossRefPubMed

15.

Pavot V, Rochereau N, Genin C et al (2012) New insights in mucosal vaccine development. Vaccine 30:142–154. https://doi.org/10.1016/j.vaccine.2011.11.003 CrossRefPubMed

16.

Hamada D, Hamaguchi M, Suzuki KN et al (2010) Cytoskeleton-modulating effectors of enteropathogenic and enterohemorrhagic Escherichia coli: a case for EspB as an intrinsically less-ordered effector. FEBS J 277:2409–2415. https://doi.org/10.1111/j.1742-4658.2010.07655.x CrossRefPubMed

17.

Frankel G, Phillips AD, Rosenshine I et al (1998) Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol 30:911–921. https://doi.org/10.1046/j.1365-2958.1998.01144.x CrossRefPubMed

18.

Kenny B, Finlay BB (1995) Protein secretion by enteropathogenic Escherichia coli is essential for transducing signals to epithelial cells. Proc Natl Acad Sci USA 92:7991–7995CrossRefPubMedPubMedCentral

19.

Asper DJ, Karmali MA, Townsend H et al (2011) Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol 18:1052–1057. https://doi.org/10.1128/CVI.00068-11 CrossRefPubMedPubMedCentral

20.

Reddy PK, Ramlal S, Sripathy MH, Batra H (2012) A simple and universal ligation mediated fusion of genes based on hetero-staggered PCR for generating immunodominant chimeric proteins. Gene 509:104–109. https://doi.org/10.1016/j.gene.2012.08.011 CrossRefPubMed

21.

Reichelt P, Schwarz C, Donzeau M (2006) Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 46:483–488. https://doi.org/10.1016/j.pep.2005.09.027 CrossRefPubMed

22.

Tadepalli G, Konduru B, Murali HS, Batra HV (2017) Intraperitoneal administration of a novel chimeric immunogen (rOP) elicits IFN-γ and IL-12p70 protective immune response in BALB/c mice against virulent Brucella. Immunol Lett 192:79–87. https://doi.org/10.1016/j.imlet.2017.10.013 CrossRefPubMed

23.

Amani J, Mousavi SL, Rafati S, Salmanian AH (2011) Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci 180:620–627. https://doi.org/10.1016/j.plantsci.2011.01.004 CrossRefPubMed

24.

Reddy PN, Paul S, Sripathy MH, Batra HV (2015) Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model. Toxicon 103:106–113. https://doi.org/10.1016/j.toxicon.2015.06.008 CrossRefPubMed

25.

Martorelli L, Garbaccio S, Vilte DA et al (2017) Immune response in calves vaccinated with type three secretion system antigens and shiga toxin 2b subunit of Escherichia coli O157:H7. PLoS One 12:e0169422. https://doi.org/10.1371/journal.pone.0169422 CrossRefPubMedPubMedCentral

26.

Ruan X, Sack DA, Zhang W (2015) Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity. PLoS One 10:e0121623. https://doi.org/10.1371/journal.pone.0121623 CrossRefPubMedPubMedCentral

27.

Amani J, Salmanian AH, Rafati S, Mousavi SL (2010) Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine 28:6923–6929. https://doi.org/10.1016/j.vaccine.2010.07.061 CrossRefPubMed

28.

Snedeker KG, Campbell M, Sargeant JM (2012) A systematic review of vaccinations to reduce the shedding of Escherichia coli O157 in the faeces of domestic ruminants. Zoonoses Public Health 59:126–138. https://doi.org/10.1111/j.1863-2378.2011.01426.x CrossRefPubMed

29.

Yekta MA, Goddeeris BM, Vanrompay D, Cox E (2011) Immunization of sheep with a combination of intiminγ, EspA and EspB decreases Escherichia coli O157:H7 shedding. Vet Immunol Immunopathol 140:42–46. https://doi.org/10.1016/j.vetimm.2010.11.010 CrossRefPubMed

30.

Vilte DA, Larzábal M, Garbaccio S et al (2011) Reduced faecal shedding of Escherichia coli O157:H7 in cattle following systemic vaccination with γ-intimin C280 and EspB proteins. Vaccine 29:3962–3968. https://doi.org/10.1016/j.vaccine.2011.03.079 CrossRefPubMed

31.

Cataldi A, Yevsa T, Vilte DA et al (2008) Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 26:5662–5667. https://doi.org/10.1016/j.vaccine.2008.07.027 CrossRefPubMed

32.

Ahmed B, Loos M, Vanrompay D, Cox E (2014) Oral immunization with Lactococcus lactis-expressing EspB induces protective immune responses against Escherichia coli O157:H7 in a murine model of colonization. Vaccine 32:3909–3916. https://doi.org/10.1016/j.vaccine.2014.05.054 CrossRefPubMed

33.

Lin R, Zhang Y, Long B et al (2017) Oral immunization with recombinant lactobacillus acidophilus expressing espA-Tir-M confers protection against enterohemorrhagic Escherichia coli O157:H7 challenge in mice. Front Microbiol 8:417. https://doi.org/10.3389/fmicb.2017.00417 CrossRefPubMedPubMedCentral

34.

Chiu H-J, Syu W-J (2005) Functional analysis of EspB from enterohaemorrhagic Escherichia coli. Microbiology 151:3277–3286. https://doi.org/10.1099/mic.0.28115-0 CrossRefPubMed

35.

Baumann D, Salia H, Greune L et al (2018) Multitalented EspB of enteropathogenic Escherichia coli (EPEC) enters cells autonomously and induces programmed cell death in human monocytic THP-1 cells. Int J Med Microbiol 308:387–404. https://doi.org/10.1016/j.ijmm.2018.03.005 CrossRefPubMed

36.

Viswanathan VK, Koutsouris A, Lukic S et al (2004) Comparative analysis of EspF from enteropathogenic and enterohemorrhagic Escherichia coli in alteration of epithelial barrier function. Infect Immun 72:3218–3227. https://doi.org/10.1128/IAI.72.6.3218-3227.2004 CrossRefPubMedPubMedCentral

37.

Tezuka H, Abe Y, Asano J et al (2011) Prominent role for plasmacytoid dendritic cells in mucosal T cell-independent IgA induction. Immunity 34:247–257. https://doi.org/10.1016/j.immuni.2011.02.002 CrossRefPubMed

38.

Ruane D, Brane L, Reis BS et al (2013) Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J Exp Med 210:1871–1888. https://doi.org/10.1084/jem.20122762 CrossRefPubMedPubMedCentral

39.

Yamamoto M, Vancott JL, Okahashi N et al (1996) The role of Th1 and Th2 cells for mucosal IgA responses. Ann N Y Acad Sci 778:64–71. https://doi.org/10.1111/j.1749-6632.1996.tb21115.x CrossRefPubMed

40.

Sollid LM, Kvale D, Brandtzaeg P et al (1987) Interferon-gamma enhances expression of secretory component, the epithelial receptor for polymeric immunoglobulins. J Immunol (Baltimore Md 1950) 138:4303–4306

41.

Rüter C, Lubos ML, Norkowski S, Schmidt MA (2018) All in—Multiple parallel strategies for intracellular delivery by bacterial pathogens. Int J Med Microbiol. https://doi.org/10.1016/j.ijmm.2018.06.007 CrossRefPubMed

42.

Etcheverría AI, Padola NL (2013) Shiga toxin-producing Escherichia coli: factors involved in virulence and cattle colonization. Virulence 4:366–372CrossRefPubMedPubMedCentral

43.

Martorelli L, Garimano N, Fiorentino GA et al (2018) Efficacy of a recombinant Intimin, EspB and Shiga toxin 2B vaccine in calves experimentally challenged with Escherichia coli O157:H7. Vaccine 36:3949–3959CrossRefPubMed

44.

García-Angulo VA, Kalita A, Kalita M et al (2014) Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7. Infect Immun 82:2016–2026. https://doi.org/10.1128/IAI.01437-13 CrossRefPubMedPubMedCentral

45.

Babiuk S, Asper DJ, Rogan D et al (2008) Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice. Microb Pathog 45:7–11. https://doi.org/10.1016/j.micpath.2008.01.005 CrossRefPubMed

46.

Yoshida M, Claypool SM, Wagner JS et al (2004) Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20:769–783. https://doi.org/10.1016/j.immuni.2004.05.007 CrossRefPubMed

47.

Fan H, Wang L, Luo J, Long B (2012) Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins. Mol Biol Rep 39:989–997. https://doi.org/10.1007/s11033-011-0824-0 CrossRefPubMed

48.

Mantis NJ, Rol N, Corthésy B (2011) Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 4:603–611. https://doi.org/10.1038/mi.2011.41 CrossRefPubMedPubMedCentral

49.

Gould LH, Mody RK, Ong KL et al (2013) Increased recognition of non-O157 shiga toxin–producing Escherichia coli infections in the United States during 2000–2010: epidemiologic features and comparison with E. coli O157 Infections. Foodborne Pathog Dis 10:453–460. https://doi.org/10.1089/fpd.2012.1401 CrossRefPubMed

50.

Brooks JT, Sowers EG, Wells JG et al (2005) Non-O157 shiga toxin–producing Escherichia coli infections in the United States, 1983–2002. J Infect Dis 192:1422–1429. https://doi.org/10.1086/466536 CrossRefPubMed

51.

McNeilly TN, Mitchell MC, Corbishley A et al (2015) Optimizing the protection of cattle against Escherichia coli O157:H7 colonization through immunization with different combinations of H7 Flagellin, Tir, Intimin-531 or EspA. PLoS One 10:e0128391. https://doi.org/10.1371/journal.pone.0128391 CrossRefPubMedPubMedCentral

Title: Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice
Authors: Aravind Shekar
Shylaja Ramlal
Joseph Kingston Jeyabalaji
Murali Harishchandra Sripathy
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 1/2019
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-018-0559-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

The sequence analysis of Epstein–Barr virus EBNA1 gene: could viral screening markers for nasopharyngeal carcinoma be identified?

From basic molecular biology to curative antiviral therapy: the success story of Hepatitis C virology

Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations

Activation of brain endothelium by Escherichia coli K1 virulence factor cglD promotes polymorphonuclear leukocyte transendothelial migration

Bartonella quintana and Bartonella vinsonii subsp. vinsonii bloodstream co-infection in a girl from North Carolina, USA

Legionella feeleii: pneumonia or Pontiac fever? Bacterial virulence traits and host immune response

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage